二〇二三年十一月 北京植德律师事务所 Merits & Tree Law Offices 北京植德律师事务所 关于吉林省集安益盛药业股份有限公司 2023 年第二次临时股东大会的 法律意见书 植德京（会）字[2023]0160 号 北京市东城区东直门南大街 1 号来福士中心办公楼 5 层 邮编：100007 5 th Floor, Raffles City Beijing Office Tower, No.1 Dongzhimen South Street, Dongcheng District, Beijing 100007 P.R.C 电话(Tel)：010-56500900 传真(Fax)：010-56500999 www.meritsandtree.com 北京植德律师事务所 关于吉林省集安益盛药业股份有限公司 2023 年第二次临时股东大会的 法律意见书 植德京（会）字[2023]0160 号 致：吉林省集安益盛药业股份有限公司 北京植德律师事务所(下称"本所")接受贵公司的委托，指派律师出席并见 证贵公司 2023 年第二次临时股东大会(下称"本次会议")。 本所律师参加本次会议进行见证，并根据《 ...

1、本次股东大会没有出现否决议案的情形。 2、本次股东大会没有涉及变更前次股东大会决议的情形。 3、本次股东大会采用现场表决、网络投票相结合的方式。 证券代码：002566 证券简称：益盛药业 公告编号：2023-034 吉林省集安益盛药业股份有限公司 2023 年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 一、会议召开情况 1、召开时间： 现场会议时间：2023年11月22日（星期三）下午14:30。 网络投票时间为：2023年11月22日，其中：通过深圳证券交易所交易系统进 行网络投票的具体时间为2023年11月22日上午9:15—9:25,9:30-11:30，下午 13:00-15:00；通过深圳证券交易所互联网投票的具体时间为2023年11月22日 9:15-15:00期间的任意时间。 2、召开地点：吉林省集安市文化东路17－20号公司四楼会议室。 3、召开方式：本次股东大会采用现场表决、网络投票相结合的方式。 4、召集人：吉林省集安益盛药业股份有限公司董事会。 5、主持人：董事长张益胜先生。 6、本次股东 ...

证券代码：002566 证券简称：益盛药业 公告编号：2023-033 近日，全国高新技术企业认定管理工作领导小组办公室发布了《吉林省认定机 构2023年认定报备的第一批高新技术企业备案名单》，根据《高新技术企业认定管 理办法》（国科发火〔2016〕32号）和《高新技术企业认定管理工作指引》（国科 发火〔2016〕195号）有关规定，吉林省集安益盛药业股份有限公司（以下简称"公 司"或"益盛药业"）及控股子公司益盛汉参化妆品有限公司（以下简称"汉参化妆"） 被列入吉林省认定机构2023年认定报备的第一批高新技术企业备案名单（证书编号 分别为GR202322000366、GR202322000568）。 根据国家相关规定，公司及汉参化妆自获得高新技术企业认定后将连续三年享 受关于高新技术企业的相关优惠政策，即按15%的税率缴纳企业所得税。该税收优惠 政策对公司后续经营业绩将产生积极的影响。 特此公告。 吉林省集安益盛药业股份有限公司董事会 吉林省集安益盛药业股份有限公司 关于公司及控股子公司通过高新技术企业认定的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗 ...

Financial Performance - The company's revenue for Q3 2023 was ¥181,720,368.76, a decrease of 6.58% compared to the same period last year[4]. - The net profit attributable to shareholders for Q3 2023 was ¥11,041,222.69, down 33.17% year-on-year[4]. - The net profit after deducting non-recurring gains and losses was ¥7,494,097.30, a decline of 49.19% compared to the previous year[4]. - Total operating revenue for Q3 2023 reached CNY 651,148,875.84, an increase of 4.5% compared to CNY 622,933,598.82 in Q3 2022[18]. - Net profit for Q3 2023 was CNY 60,199,120.13, down 8.1% from CNY 65,887,086.43 in the same period last year[20]. - The company reported a profit before tax of CNY 70,153,073.34, down from CNY 76,639,367.10 in Q3 2022[20]. - Basic earnings per share for Q3 2023 were CNY 0.1767, compared to CNY 0.1823 in the same period last year[20]. Assets and Liabilities - The total assets at the end of Q3 2023 were ¥3,033,011,020.84, an increase of 2.24% from the end of the previous year[5]. - The company's total assets increased to CNY 3,033,011,020.84, up from CNY 2,966,606,675.95 year-over-year[17]. - Total liabilities rose to CNY 739,931,425.34, compared to CNY 717,178,620.58 in Q3 2022, reflecting a growth of 3.0%[17]. - The total equity attributable to shareholders of the parent company increased to CNY 2,196,900,151.35, up from CNY 2,154,978,185.80[17]. Cash Flow - The cash flow from operating activities for the year-to-date was ¥162,346,702.32, up 86.16%[4]. - Operating cash flow for the period reached ¥162,346,702.32, a significant increase of 86.1% compared to ¥87,206,481.59 in the previous period[21]. - Total cash inflow from operating activities was ¥796,571,102.42, up from ¥727,406,113.62, reflecting a growth of 9.5%[21]. - Cash outflow from operating activities decreased to ¥634,224,400.10 from ¥640,199,632.03, resulting in improved net cash flow[21]. - The ending cash and cash equivalents balance was ¥446,022,778.54, up from ¥289,992,896.36, indicating a growth of 54.0%[22]. Shareholder and Equity Issues - The company is addressing issues related to shareholder equity by implementing a reduction of held shares to ensure accurate information disclosure, particularly concerning shareholder Liu Jianming[12]. - The company has acknowledged the penalties imposed by the China Securities Regulatory Commission due to previous misreporting of shareholder equity[12]. - The company has made efforts to clarify the ownership structure among its top shareholders, ensuring compliance with regulatory requirements[12]. - The company continues to focus on maintaining accurate and complete financial disclosures to enhance investor confidence and market integrity[12]. Government Subsidies and Financial Income - The company received government subsidies amounting to ¥2,969,147.86 in Q3 2023, contributing to non-recurring gains[6]. - The financial expenses decreased by 95.82% to ¥212,693.08, primarily due to increased interest income from deposits[8]. - The company's investment income fell by 34.43% to ¥1,871,569.75, attributed to reduced returns from financial products[8]. Current Assets and Inventory - As of September 30, 2023, the company's total current assets amounted to CNY 2,400,754,341.42, an increase of 4.27% from CNY 2,302,612,638.12 on January 1, 2023[15]. - The company's cash and cash equivalents reached CNY 446,022,778.54, up from CNY 343,263,877.76 at the beginning of the year, reflecting a growth of 30.05%[15]. - Inventory levels stood at CNY 1,613,630,489.16, showing a slight increase from CNY 1,603,100,929.50 at the start of the year[15]. - The company's fixed assets decreased to CNY 484,841,675.35 from CNY 509,049,720.37, indicating a decline of 4.73%[15]. - The company has reported a significant increase in trading financial assets, which rose to CNY 100,949,663.51 from CNY 59,843,164.59, marking an increase of 68.67%[15]. Research and Development - Research and development expenses for Q3 2023 were CNY 15,350,755.29, slightly down from CNY 15,482,990.67 in Q3 2022[18].

证券代码：002566 证券简称：益盛药业 公告编号：2023-029 吉林省集安益盛药业股份有限公司 第八届董事会第九次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 吉林省集安益盛药业股份有限公司（以下称"公司"）第八届董事会第九次 会议通知以当面送达、电话、邮件的方式于2023年10月19日向各董事发出，会议 于2023年10月26日以现场会议的方式在公司四楼会议室召开。会议应参加审议董 事9人，实际参加审议董事9人。本次会议的召开符合《公司法》及《公司章程》 的规定，合法有效。会议由董事长张益胜先生主持，审议并通过了如下议案： 一、会议以9票同意、0票反对、0票弃权的表决结果，审议通过了《2023年 第三季度报告》。 公司董事会同意向中国工商银行股份有限公司集安支行申请不超过1.7亿元 的流动资金贷款，向中国银行股份有限公司集安支行、中国农业银行股份有限公 司集安市支行分别申请不超过2亿元流动资金贷款，合计5.7亿元，用于购买原材 料和日常经营所需流动资金。上述贷款为信用借款，贷款期限一年，并授权财务 总监全权办理贷款手续。 该项议案需 ...

一、会议以3票同意、0票反对、0票弃权的表决结果，审议通过了《2023年 第三季度报告》。 经审核，监事会认为董事会编制和审核公司2023年第三季度报告的程序符合 法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了上市 公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 二、备查文件 公司第八届监事会第九次会议决议。 特此公告。 吉林省集安益盛药业股份有限公司监事会 证券代码：002566 证券简称：益盛药业 公告编号：2023-030 吉林省集安益盛药业股份有限公司 第八届监事会第九次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 吉林省集安益盛药业股份有限公司（以下称"公司"）第八届监事会第九次 会议通知以当面送达、电话的方式于2023年10月19日向各监事发出，会议于2023 年10月26日以现场会议方式在公司四楼会议室召开。会议应当出席的监事3人， 实际出席的监事3人。本次会议的召集、召开程序符合《公司法》等有关法律、 法规及《公司章程》的规定。会议由监事会主席于晓静女士主持，审议并通过了 如下议案： 二〇二三 ...

证券代码：002566 证券简称：益盛药业 公告编号：2023-032 吉林省集安益盛药业股份有限公司 关于召开 2023 年第二次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东大会届次：2023 年第二次临时股东大会。 2、股东大会的召集人：公司董事会。2023年10月26日，公司第八届董事会 第九次会议审议通过了《关于召开2023年第二次临时股东大会的议案》。 3、会议召开的合法、合规性：本次股东大会会议的召开符合有关法律、行 政法规、部门规章、规范性文件和公司章程的有关规定。 4、会议召开的日期、时间： 现场会议召开时间：2023 年 11 月 22 日（星期三）下午 14:30 。 网络投票时间：2023 年 11 月 22 日。 其中：通过深圳证券交易所交易系统进行网络投票的具体时间为 2023 年 11 月 22 日上午 9:15—9:25,9:30-11:30，下午 13:00-15:00；通过深圳证券交易所 互联网投票的具体时间为 2023 年 11 月 22 日 9:15-15:00 期间 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥469,428,507.08, representing a 9.57% increase compared to ¥428,409,146.26 in the same period last year[24]. - The net profit attributable to shareholders of the listed company was ¥47,428,322.86, an increase of 8.25% from ¥43,812,015.69 year-on-year[24]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥36,945,048.36, up 12.58% from ¥32,817,432.17 in the previous year[24]. - The net cash flow from operating activities increased by 60.55% to ¥116,279,461.95, compared to ¥72,426,598.89 in the same period last year[24]. - The total assets at the end of the reporting period were ¥3,012,806,349.84, a 1.56% increase from ¥2,966,606,675.95 at the end of the previous year[24]. - The net assets attributable to shareholders of the listed company were ¥2,185,858,928.66, reflecting a 1.43% increase from ¥2,154,978,185.80 at the end of the previous year[24]. - The basic earnings per share for the reporting period was ¥0.1433, an increase of 8.23% from ¥0.1324 in the same period last year[24]. - The company's cash flow from operating activities increased significantly by 60.55%, amounting to ¥116,279,461.95, compared to ¥72,426,598.89 in the previous year[47]. - The company reported a net increase in cash and cash equivalents of 57.99%, totaling ¥83,657,004.16, compared to ¥52,950,604.57 in the previous year[47]. - The total comprehensive income for the first half of 2023 was CNY 45,953,590.56, down from CNY 81,907,555.86 in the first half of 2022, indicating a decline of 43.8%[138]. Market and Product Development - The company has developed 11 dosage forms and 117 varieties, with 49 products included in the National Basic Medical Insurance Drug List[36]. - The company has established a complete ginseng industry chain, expanding from pharmaceuticals to cosmetics and health foods[36]. - Yisheng Ginseng Cosmetics has developed over 500 products, including facial cleansers, whitening, anti-wrinkle, acne treatment, and body care products, expanding its ginseng industry chain[38]. - The company has obtained 8 invention patents for ginseng-based cosmetics, filling a market gap in China[38]. - The company plans to continue expanding its market presence and investing in new product development to drive future growth[134]. - The company aims to leverage technological innovation and market expansion to ensure sustainable development amid a challenging economic environment[32]. Research and Development - The company has received 14 patents and 2 scientific achievements related to ginseng cultivation technology[37]. - The Zhenyuan Capsule, a national medical insurance category B product, has been involved in 147 published papers, with 11 indexed by SCI, demonstrating its efficacy in treating coronary heart disease and related conditions[38]. - The Xinyue Capsule has published 238 academic papers, with 23 indexed by SCI, focusing on coronary heart disease and angina treatment[39]. - The Shengmai Injection, a national medical insurance category A product, is recommended for severe cases of COVID-19 in clinical treatment guidelines[40]. - The company has established long-term partnerships with numerous top-tier hospitals and universities, enhancing its R&D capabilities[47]. Financial Management and Strategy - The company plans not to distribute cash dividends or issue bonus shares[7]. - The company emphasizes brand building as a systematic project, continuously investing to enhance brand market awareness and influence[43]. - The company has established a diverse sales channel strategy, including academic promotion and OTC market expansion, to enhance sales performance[42]. - The company has implemented strict internal control systems to protect the rights of shareholders and creditors, ensuring timely disclosure of major information[77]. - The company aims to enhance shareholder value through strategic investments and operational improvements[149]. Risks and Compliance - The company faces risks related to industry policy adjustments, rising production costs, R&D challenges, inventory price declines, talent shortages, and environmental regulations[65][66]. - The company plans to actively monitor and respond to potential risks to achieve its operational goals for 2023[66]. - The company has not received any administrative penalties for environmental issues during the reporting period[74]. - The company has established a comprehensive emergency response mechanism for environmental pollution incidents, including a specific emergency plan and regular employee training[75]. Shareholder Information - The total number of shares remained unchanged at 330,951,600 during the reporting period[106]. - The major shareholder Zhang Yisheng holds 39.08% of the shares, totaling 129,348,530 shares[111]. - The total number of ordinary shareholders at the end of the reporting period was 26,051[110]. - The company aims to protect the interests of minority investors while resolving the shareholding representation issue[114]. Accounting and Financial Reporting - The financial report for the first half of 2023 has not been audited[123]. - The financial statements are prepared in RMB, with the balance sheet dated June 30, 2023[124]. - The company adheres to the accounting standards set by the Ministry of Finance, ensuring the financial statements are true and complete[162]. - The company recognizes deferred tax assets related to deductible temporary differences if new information indicates that the economic benefits can be realized within 12 months post-acquisition, reducing goodwill accordingly[168]. Inventory and Assets - The company recognizes inventory when it is likely that economic benefits will flow to the enterprise and the cost can be reliably measured[195]. - Inventory is measured at the lower of cost and net realizable value, with provisions for inventory write-downs recorded when costs exceed net realizable value[196]. - The company uses a perpetual inventory system for tracking inventory[197]. - The company conducts physical inventory counts of consumable biological assets between July and October each year[199].

吉林省集安益盛药业股份有限公司 （以下无正文） （本页无正文，为《独立董事关于控股股东及其他关联方占用公司资金和公司对 外担保情况的专项说明和独立意见》之签署页） 独立董事： 独立董事关于控股股东及其他关联方占用公司资金 和公司对外担保情况的专项说明和独立意见 根据中国证券监督管理委员会《上市公司独立董事规则》、《上市公司自律 监管指引第1号—主板上市公司规范运作》、《深圳证券交易所股票上市规则》 和《吉林省集安益盛药业股份有限公司章程》等有关规定，作为吉林省集安益盛 药业股份有限公司（以下简称"公司"）的独立董事，我们本着对公司、全体股 东及投资者负责的态度，按照实事求是的原则，对公司2023年半年度控股股东及 其他关联方占用公司资金及公司对外担保情况进行了认真的检查和落实，并作如 下专项说明及独立意见： 1、报告期内公司不存在控股股东及其他关联方占用公司资金情况，也不存 在以前期间发生并延续到报告期的控股股东及其他关联方占用公司资金的情况。 2、报告期内公司不存在为股东、实际控制人及其关联方、任何非法人单位 或个人提供担保的情况，也不存在以前期间发生并延续到报告期的对外担保事项。 公司当期和累计对外担保金 ...

吉林省集安益盛药业股份有限公司（以下称"公司"）第八届董事会第八次 会议通知以当面送达、电话、邮件的方式于2023年8月17日向各董事发出，会议 于2023年8月24日以现场会议的方式在公司四楼会议室召开。会议应参加审议董 事9人，实际参加审议董事9人。本次会议的召开符合《公司法》及《公司章程》 的规定，合法有效。会议由董事长张益胜先生主持，审议并通过了如下议案： 会议以9票同意、0票反对、0票弃权的表决结果，审议通过了《2023年半年 度报告及其摘要》。 《2023年半年度报告全文》详见公司指定信息披露网站巨潮资讯网 (www.cninfo.com.cn)。 《2023年半年度报告摘要》详见公司指定的信息披露媒体巨潮资讯网 （www.cninfo.com.cn）及《中国证券报》、《上海证券报》、《证券时报》。 特此公告。 吉林省集安益盛药业股份有限公司董事会 证券代码：002566 证券简称：益盛药业 公告编号：2023-026 吉林省集安益盛药业股份有限公司 第八届董事会第八次会议决议公告 二〇二三年八月二十四日 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或者重大 ...